BiotechTube

montelukast + placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Perennial Allergic Rhinitis

Conditions

Perennial Allergic Rhinitis

Trial Timeline

May 1, 2003 → Jan 1, 2009

NCT ID
NCT00590772

About montelukast + placebo

montelukast + placebo is a approved stage product being developed by Merck for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00590772. Target conditions include Perennial Allergic Rhinitis.

What happened to similar drugs?

13 of 20 similar drugs in Perennial Allergic Rhinitis were approved

Approved (13) Terminated (1) Active (7)
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅Placebo + Montelukast + Fluticasone propionateMerckApproved
✅loratadine + loratadine + loratadineMerckApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved
✅FexofenadineSanofiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00599534Phase 2Withdrawn
NCT00406094ApprovedUNKNOWN
NCT00189462ApprovedCompleted
NCT00189475ApprovedCompleted
NCT00590772ApprovedCompleted
NCT01011452ApprovedCompleted

Competing Products

20 competing products in Perennial Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide HFA 160 μgSumitomo PharmaPhase 3
40
Budesonide + PlaceboAstraZenecaApproved
43
Ciclesonide + PlaceboAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
Ciclesonide nasal + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
43
CiclesonideAstraZenecaPhase 3
40
MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal sprayMerckPhase 3
40
Placebo + Montelukast + Fluticasone propionateMerckApproved
35
MK-8237 6 DU + MK-8237 12 DU + PlaceboMerckPhase 1
29
loratadine + loratadine + loratadineMerckApproved
43